99.19

2.76% -2.82

Pre-market: 100.44 1.25 +1.26%

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $99.19, with a volume of 392.64K. It is down -2.76% in the last 24 hours and down -6.03% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Previous Close:

$102.01

Open:

$102.01

24h Volume:

392.64K

Relative Volume:

0.54

Market Cap:

$6.38B

Revenue:

$74.06M

Net Income/Loss:

$-114.71M

P/E Ratio:

-54.99

EPS:

-1.8039

Net Cash Flow:

$-117.90M

1W Performance:

-2.93%

1M Performance:

-6.03%

6M Performance:

+16.15%

1Y Performance:

+116.05%

1-Day Range:

$98.89

$102.42

1-Week Range:

$96.69

$104.16

52-Week Range:

$45.14

$107.84

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

131

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	99.19	6.56B	74.06M	-114.71M	-117.90M	-1.8039
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-12-25	Initiated	Leerink Partners	Outperform
Jun-17-25	Initiated	Citigroup	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

May 22, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat

May 22, 2026

May 21, 2026

Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India

May 21, 2026

Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa

May 21, 2026

Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

May 21, 2026

PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill

May 21, 2026

May 20, 2026

Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN

May 20, 2026

HC Wainwright Issues Positive Outlook for PTGX Earnings - MarketBeat

May 20, 2026

Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN

May 20, 2026

May 17, 2026

A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit - Sahm

May 17, 2026

May 16, 2026